These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19418615)

  • 1. No cure in sight for the world's drug problem.
    Holmes D
    Lancet Oncol; 2009 May; 10(5):450. PubMed ID: 19418615
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapatinib shows promise for inflammatory breast cancer.
    Cancer Biol Ther; 2007 Jan; 6(1):8. PubMed ID: 17612006
    [No Abstract]   [Full Text] [Related]  

  • 3. Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
    Doss S; Robertson J; Adam J
    Lancet Oncol; 2012 Aug; 13(8):766-7. PubMed ID: 23024989
    [No Abstract]   [Full Text] [Related]  

  • 4. Lapatinib for inflammatory breast cancer.
    Hall PS; Hanby A; Cameron DA
    Lancet Oncol; 2009 Jun; 10(6):538-9. PubMed ID: 19482243
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
    Arai H; Yamaki M; Nishimura Y
    Nihon Yakurigaku Zasshi; 2010 Sep; 136(3):175-84. PubMed ID: 20838021
    [No Abstract]   [Full Text] [Related]  

  • 6. Lapatinib in the treatment of HER-2 overexpressing breast cancer.
    Vrdoljak E; Boban M; Ban M
    J BUON; 2011; 16(3):393-9. PubMed ID: 22006739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib.
    Moy B; Kirkpatrick P; Kar S; Goss P
    Nat Rev Drug Discov; 2007 Jun; 6(6):431-2. PubMed ID: 17633789
    [No Abstract]   [Full Text] [Related]  

  • 8. Why are promising new drugs for dying patients still out of reach?
    Peckham C
    MedGenMed; 2007 Jun; 9(2):49. PubMed ID: 17955104
    [No Abstract]   [Full Text] [Related]  

  • 9. [Advances in research on treatment of breast cancer with lapatinib].
    Ma CD; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
    [No Abstract]   [Full Text] [Related]  

  • 10. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
    Mukherjee A; Dhadda AS; Shehata M; Chan S
    Expert Opin Pharmacother; 2007 Sep; 8(13):2189-204. PubMed ID: 17714070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 12. Atypical cutaneous vasculitis under lapatinib.
    Peuvrel L; Quereux G; Brocard A; Saint-Jean M; Freour E; Josselin N; Audouin AF; El Kouri C; Dreno B
    Eur J Dermatol; 2013; 23(4):540-1. PubMed ID: 23965414
    [No Abstract]   [Full Text] [Related]  

  • 13. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
    Sardesai SD; Storniolo AM
    Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
    Mayer EL; Lin NU; Burstein HJ
    J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib.
    Le QA
    Med Decis Making; 2016 Jul; 36(5):629-40. PubMed ID: 26753626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
    D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
    Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
    Mutlu H; Büyükçelik A; Akça Z; Erden A
    J Oncol Pharm Pract; 2015 Feb; 21(1):72-3. PubMed ID: 24154651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.
    Yip AY; Tse LA; Ong EY; Chow LW
    Anticancer Drugs; 2010 Jun; 21(5):487-93. PubMed ID: 20220514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.